Business Context and Reporting Period
This Form 8-K is a current report filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals Inc. in metadata) on November 27, 2017. The filing discloses corporate governance actions regarding executive compensation and severance arrangements adopted by the Compensation Committee of the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of new employment and severance agreements.
Material Changes and Corporate Actions
Change in Control Severance Plan
On November 27, 2017, the Company adopted a Change in Control Severance Plan for all full-time employees, excluding the President and CEO. Key provisions include:
- Trigger: Termination without Cause or for Good Reason within six months following a Change in Control.
- Severance Payment: Three weeks of base salary per year of service.
- Executive Limits: Minimum of 26 weeks and maximum of 52 weeks of base salary for officers/VPs.
- Other Employee Limits: Minimum of 8 weeks and maximum of 26 weeks of base salary.
- Additional Benefits: Prorated annual incentive awards (at target), earned but unpaid incentives, and six months of COBRA health insurance premiums.
- Tax Treatment: Payments subject to Section 280G excise tax will be reduced unless the unreduced amount provides a 5% greater after-tax benefit. No excise tax gross-ups are provided.
Amended Employment Agreement for CEO
On November 29, 2017, the Company entered into a Third Amended and Restated Employment Agreement with Stephen From, President and CEO. Key changes include:
- Change in Control Payment: A severance payment based on transaction value, capped at 1.5% of the transaction value.
- Termination Benefits (Without Cause/Good Reason):
- 18 months of salary continuation.
- 1.5x the performance bonus for the year of termination.
- 18 months of COBRA subsidy payments.
- 18 months of accelerated vesting for unvested stock options and restricted stock awards.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, market outlook, or general risk factors. The primary purpose of the new plans is to ensure the continued dedication of executives and minimize disruption in the event of a Change in Control. The documents are qualified by reference to the full text of the agreements filed as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Verify the exact definition of "Change in Control" in the filed exhibits (10.1 and 10.2) to understand the specific triggers for these payouts.
- Review the full text of the Third Amended and Restated Employment Agreement to confirm the calculation methodology for the 1.5% transaction value cap.
- Assess the potential financial impact of the 18-month salary continuation and accelerated vesting for the CEO in the context of the Company's current cash position.
- Confirm whether the Company's status as an "Emerging Growth Company" affects the disclosure or implementation of these plans.